Is doxycycline safe to use during the third trimester of pregnancy?

Doxycycline Safety in Third Trimester of Pregnancy

Doxycycline should generally be avoided during the third trimester of pregnancy unless treating a life-threatening infection where no safer alternative exists, as the FDA classifies it as Pregnancy Category D and traditional concerns about tetracycline-class drugs persist, though emerging evidence suggests the actual risk may be lower than historically believed.

Key Considerations

FDA Classification and Traditional Concerns

The FDA drug label clearly designates doxycycline as Pregnancy Category D 1. Tetracycline-class drugs have historically been contraindicated during pregnancy due to concerns about:

• Potential musculoskeletal developmental effects in the fetus
• Cosmetic staining of primary dentition when exposed during second or third trimester
• Development of acute fatty liver of pregnancy in the mother 2

However, these adverse effects were primarily observed with older tetracyclines (tetracycline itself), not specifically doxycycline 2.

Emerging Evidence on Actual Risk

Recent evidence suggests doxycycline may be safer than the blanket tetracycline-class contraindication implies:

• An expert review (TERIS) concluded that therapeutic doses during pregnancy are unlikely to pose substantial teratogenic risk, though data are insufficient to state no risk exists 2, 1
• A 2016 systematic review found no evidence of teratogenicity associated with doxycycline use during pregnancy 2
• No reports of maternal hepatic toxicity with doxycycline have been published (unlike high-dose IV tetracycline) 2
• A large 2025 population-based cohort of 265,686 pregnancies found no association between first-trimester doxycycline exposure and major congenital malformations (adjusted RR 1.07; 95% CI 0.93-1.23) 3

Important caveat for third trimester specifically: The 2025 study found third-trimester exposure (n=112) was linked to higher risk of very-low birthweight, though other late-pregnancy outcomes were comparable 3.

Clinical Decision-Making Algorithm

For Life-Threatening Infections (e.g., Rocky Mountain Spotted Fever, severe ehrlichiosis):

• Use doxycycline - the disease-related risks to mother and fetus outweigh theoretical drug risks 2
• Doxycycline has been used successfully in several pregnant women without adverse maternal effects 2
• Delay in treatment can lead to severe disease and death 2

For Non-Life-Threatening Infections:

• Avoid doxycycline and use alternatives 4
• For Lyme disease: Use amoxicillin or cefuroxime axetil instead 4
• For RMSF in pregnancy: Chloramphenicol is an alternative, though caution is needed late in third trimester due to theoretical gray baby syndrome risk 2
• For mild anaplasmosis: Rifampin may be considered as alternative 2

Common Pitfalls to Avoid

1. Don't automatically refuse doxycycline for life-threatening rickettsial diseases - maternal and fetal mortality from untreated disease far exceeds theoretical drug risks
2. Don't assume all tetracyclines carry identical risks - doxycycline binds calcium less avidly than older tetracyclines 5
3. Don't overlook the specific third-trimester concern - the association with very-low birthweight warrants particular caution in late pregnancy 3
4. Don't use chloramphenicol indiscriminately - it's NOT effective for ehrlichiosis or anaplasmosis 2

Risk-Benefit Counseling Points

When doxycycline use is being considered:

• Most data are from first-trimester, short-term exposure - limited data exist for third-trimester or prolonged use 1
• Risk of cosmetic tooth staining cannot be definitively determined due to limited data 2
• Patient counseling and shared decision-making are essential 2
• For potentially life-threatening illnesses, consideration of disease-related risks for mother and fetus is paramount 2

Strength of Evidence

The evidence base has important limitations:

• No controlled studies have assessed doxycycline safety in pregnant women 2
• Available data are primarily observational 2
• The 2025 cohort study is the largest and most recent, but third-trimester exposure numbers were small (n=112) 3
• Guidelines consistently note that data quality is "limited to fair" 2, 1

In real-world practice: The decision hinges on infection severity. For serious, potentially fatal infections where doxycycline is the most effective treatment, use it. For routine infections, safer alternatives exist and should be preferred.